OGA
O-GlcNAc hydrolase; O-GlcNAcase
OGA (O-GlcNAcase) is an enzyme catalyses the removal of the O-GlcNAc post-translational modification. O-GlcNAcylation is the dynamic and ubiquitous post-translational glycosylation of nucleocytoplasmic proteins on serine/threonine residues; it is implicated in regulation of the cell cycle. O-GlcNAcylation is the dynamic and ubiquitous post-translational glycosylation of nucleocytoplasmic proteins on serine/threonine residues; it is implicated in regulation of the cell cycle.
All Product Categories
-
OGA Related Products (17)
Related Products (17)
- 1
-
(Z)-PUGNAc
0 Images(Z)-PUGNAc is a potent O-GlcNAcase inhibitor. (Z)-PUGNAc is a vastly more potent inhibitor of O-GlcNAcase than the E form.
-
Egalognastat
0 ImagesSynonyms: ASN90Egalognastat (ASN90) is a selective, brain-penetrant and orally active O-GlcNAcase (OGA) enzyme inhibitor with an IC50 value of 10.2 nM. Egalognastat increases O-GlcNAcylation of intracellular proteins like tau and α-synuclein, preventing their aggregation and toxicity. Egalognastat does not inhibit hexosaminidase (Hex). Egalognastat can be used for the research of neurodegenerative diseases, such as tauopathies and α-synucleinopathies (e.g., Alzheimer’s disease and Parkinson’s disease).
-
O-GlcNAcase-IN-6
0 ImagesCat. No.: HY-183557CAS No.: 2407072-65-3O-GlcNAcase-IN-6 is an orally active, blood-brain barrier-permeable O-GlcNAcase (OGA) inhibitor with an IC50 of 5.4 nM. O-GlcNAcase-IN-6 inhibits OGA activity, thereby increasing the level of O-GlcNAc glycosylation in brain tissues. O-GlcNAcase-IN-6 can be used for the research of Alzheimer's disease.
-
NAG-thiazoline
0 ImagesCat. No.: HY-139431CAS No.: 179030-22-9NAG-thiazoline is a O-GlcNAcase inhibitor with a Ki of 180 nM. NAG-thiazoline is a potent GH20 GlcNAcase (VhGlcNAcase) inhibitor with an IC50 of 11.9 μM and a Ki of 62 µM.
-
Hydroxyectoin
0 ImagesSynonyms: Pyrostatin A; 5-HydroxyectoineHydroxyectoin (Pyrostatin A) is a competitive inhibitor of GlcNAcase, with the Ki of 1.7 μM.
-
(2R,4R)-LY3372689
0 ImagesCat. No.: HY-144682CAS No.: 3085990-58-2O-GlcNAcase-IN-4 is a O-GlcNAcase inhibitor extracted from patent WO2018140299A1 Formulaic Ic. O-GlcNAcase-IN-4 can be used for the research of neurodegenerative diseases and disorders, such as Alzheimer's disease.
-
O-GlcNAcase-IN-2
0 ImagesCat. No.: HY-161953O-GlcNAcase-IN-2 (compound 81) is an orally effective, blood-brain barrier-permeable OGA inhibitor (IC50=4.93 nM). O-GlcNAcase-IN-2 can increase the O-GlcNAcylation level of proteins and phosphorylation of tau (p-Ser199, p-Thr205 and p-Ser396) in the OA-damaged SH-SY5Y cell model. O-GlcNAcase-IN-2 can also improve cognitive impairment in APP/PS1 mice and has potential anti-Alzheimer's disease (AD) effects.
-
rel-Ceperognastat
0 ImagesCat. No.: HY-144681ACAS No.: 2241514-58-7Synonyms: rel-LY3372689rel-Ceperognastat (rel-LY3372689) (Compound Formula Ic) is a O-GlcNAcase (OGA) inhibitor that can be used to study the neurodegenerative diseases and disorders, such as Alzheimer's disease.
-
(Z)-PUGNAc (Standard)
0 ImagesCat. No.: HY-108241RCAS No.: 132489-69-1(Z)-PUGNAc (Standard) is the analytical standard of (Z)-PUGNAc (HY-108241). This product is intended for research and analytical applications. (Z)-PUGNAc is a potent O-GlcNAcase inhibitor. (Z)-PUGNAc is a vastly more potent inhibitor of O-GlcNAcase than the E form.
-
O-GlcNAcase-IN-4
0 ImagesCat. No.: HY-181600O-GlcNAcase-IN-4 (compound T-110) is a O-GlcNAcase inhibitor with an IC50 of 11.59 nM. O-GlcNAcase-IN-4 modulates the activity of O-GlcNAcase. O-GlcNAcase-IN-4 is applicable to the research of neurodegenerative diseases and disorders, Alzheimer's disease, and tau-mediated neurodegenerative diseases or disorders.
-
O-GlcNAcase-IN-3
0 ImagesCat. No.: HY-176852CAS No.: 2760514-33-6O-GlcNAcase-IN-3 (Compound I) is an OGA inhibitor. O-GlcNAcase-IN-3 can be used for Alzheimer's Disease (AD) research.
-
O-GlcNAcase-IN-5
0 ImagesCat. No.: HY-185146CAS No.: 690215-80-6O-GlcNAcase-IN-5 (Compound 1) is a selective O-GlcNAcase inhibitor. O-GlcNAcase-IN-5 can prevent the enzyme from removing the O-GlcNAc modification on tau protein, thus avoiding excessive phosphorylation of tau protein. O-GlcNAcase-IN-5 can be used for the research of Alzheimer's disease.
- 1
